Phase 2 Trial Finds JAK Inhibitor Safely Reduces Immune
A Phase 2 clinical trial published in Cell Reports Medicine found that a JAK inhibitor safely reduces immune activity in people with Down syndrome.
A Phase 2 clinical trial published in Cell Reports Medicine found that a JAK inhibitor safely reduces immune activity in people with Down syndrome.